EcoDrugPlus

Phosphodiesterase 5a

Ensembl ID : ENSVVUG00000008217
Gene Symbol: PDE5A
3 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSVVUG00000018435
Gene Symbol: PDE7A
3 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSVVUG00000000584
Gene Symbol: PDE7B
3 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSVVUG00000016818
Gene Symbol: PDE9A
3 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSVVUG00000006604
Gene Symbol: PIK3R1
3 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSVVUG00000008441
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSVVUG00000007266
Gene Symbol: PIK3R3
4 Cross references
274 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSVVUG00000028888
Gene Symbol: PIK3R5
3 Cross references
254 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSVVUG00000029466
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSVVUG00000029304
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSVVUG00000019519
Gene Symbol: PLA2G10
3 Cross references
249 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSVVUG00000022979
Gene Symbol: GART
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).